Sphere-9 PAF China Study
NCT: NCT07789925 · NOT_YET_RECRUITING
Brief Summary
The goal of this clinical trial is to find out if the Sphere-9 Catheter and Affera Integrated Mapping and Ablation System is safe and works to treat recurrent symptomatic paroxysmal atrial fibrillation (PAF) in adults who have not been helped by, cannot tolerate, or cannot take certain medicines for PAF. The main questions it aims to answer are: Is the Sphere-9 Catheter and Affera Integrated Mapping and Ablation System safe for treating PAF? Does the treatment help keep patients free from atrial fibrillation and other abnormal heart rhythms during the 12 months after the procedure? Participants will: Have their heart rhythm assessed before and after the ablation procedure. Have PAF treated using the Sphere-9 Catheter and Affera Integrated Mapping and Ablation System. Have follow-up visits at 3, 6, and 12 months after the procedure.
Frequently Asked Questions
What is Sphere-9 PAF China Study?
Sphere-9 PAF China Study is a clinical trial registered under NCT07789925. Current status: NOT_YET_RECRUITING.
What is the status of NCT07789925?
The current status of NCT07789925 (Sphere-9 PAF China Study) is: NOT_YET_RECRUITING.
When did Sphere-9 PAF China Study start?
Sphere-9 PAF China Study started on 2026-09-02.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.